{
  "id": 7979274,
  "title": "Precision BioSciences at H.C. Wainwright conference: two shots on goal",
  "url": "https://urgent.news/2026/09/17/precision-biosciences-at-h-c-wainwright-conference-two-shots-on-goal",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-17T07:54:39.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/precision-biosciences-at-hc-wainwright-conference-two-shots-on-goal-93CH-4904953"
  },
  "original_language": "en",
  "account": "On September 16, 2026, Precision BioSciences unveiled its dual gene-editing strategy at the H.C. Wainwright Global Investment Conference. The company highlighted progress in two clinical programs, focusing on chronic hepatitis B and Duchenne muscular dystrophy.\n\nPrecision's lead program, PBGENE-HBV, is in early clinical testing for chronic hepatitis B. The treatment targets cccDNA, the viral reservoir responsible for chronic infection. In May 2026, clinical data showed a one-log reduction in cccDNA-derived transcripts after two doses, with durable undetectable levels achieved after three doses. The program began dosing 16 patients across 38 administrations.\n\nPBGENE-DMD, Precision's second clinical program, targets Duchenne muscular dystrophy. The Phase I/II FUNCTION-DMD trial began dosing patients in August 2026 at Arkansas Children's Hospital and Washington University in St. Louis. The treatment focuses on exons 45 through 55, covering about 60% of DMD patients. Muscle biopsies are scheduled before treatment, at three months, and at 12 months after treatment.\n\nPrecision's gene-editing platform, ARCUS, is differentiated by its cut, smaller size, and single-component design. The company expects runway through 2028, with $112 million in cash at the end of the second quarter. Management sees both programs as \"shots on goal,\" with different therapeutic approaches and regulatory paths. Despite risks, the company believes PBGENE-HBV could produce a long-term viral cure, while PBGENE-DMD offers a clear rare-disease development path.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Halozyme at H.C. Wainwright conference: royalties drive growth",
        "url": "https://urgent.news/2026/09/16/halozyme-at-h-c-wainwright-conference-royalties-drive-growth",
        "published": "2026-09-16T14:36:19.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}